Patents by Inventor Meritxel GIRONELLA COS

Meritxel GIRONELLA COS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • In vitro method for identifying pancreatic cancer or intraductal papillary mucinous neoplasm of the pancreas
    Patent number: 11104959
    Abstract: The present invention refers to an in vitro method for screening for subjects at risk of developing pancreatic cancer or intraductal papillary mucinous neoplasm of the pancreas (IPMN) comprising: (a) measuring the expression pattern or level of at least hsa-miR-33a*, or of at least hsa-miR-320a, or of at least hsa-let-7e, or of at least hsa-let-7f, or of at least hsa-miR-1257, or of at least hsa-miR-1304, or of at least hsa-miR-151b, or of at least hsa-miR-3120-3p, or of at least hsa-miR-3133, or of at least hsa-miR-3714, or of at least hsa-miR-4468, or of at least hsa-miR-4639-5p, or of at least hsa-miR-4713-5p, or of at least hsa-miR-4714-5p, or of at least hsa-miR-4770, or of at least hsa-miR-548d-3p, or of at least hsa-miR-761, obtained from an isolated biological sample of the subjects to be screened; and (b) comparing said expression pattern or level of at least hsa-miR-33a*, or of at least hsa-miR-320a, or of at least hsa-let-7e, or of at least hsa-let-7f, or of at least hsa-miR-1257, or of at least hs
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: August 31, 2021
    Assignees: Advanced Marker Discovery, S.L., Centro de Investigación Biomedica en Red, Hospital Clinic de Barcelona
    Inventors: Meritxel Gironella Cos, Antoni Castells Garangou
  • IN VITRO METHOD FOR IDENTIFYING PANCREATIC CANCER OR INTRADUCTAL PAPILLARY MUCINOUS NEOPLASM OF THE PANCREAS
    Publication number: 20190330699
    Abstract: The present invention refers to an in vitro method for screening for subjects at risk of developing pancreatic cancer or intraductal papillary mucinous neoplasm of the pancreas (IPMN) comprising: (a) measuring the expression pattern or level of at least hsa-miR-33a*, or of at least hsa-miR-320a, or of at least hsa-let-7e, or of at least hsa-let-7f, or of at least hsa-miR-1257, or of at least hsa-miR-1304, or of at least hsa-miR-151b, or of at least hsa-miR-3120-3p, or of at least hsa-miR-3133, or of at least hsa-miR-3714, or of at least hsa-miR-4468, or of at least hsa-miR-4639-5p, or of at least hsa-miR-4713-5p, or of at least hsa-miR-4714-5p, or of at least hsa-miR-4770, or of at least hsa-miR-548d-3p, or of at least hsa-miR-761, obtained from an isolated biological sample of the subjects to be screened; and (b) comparing said expression pattern or level of at least hsa-miR-33a*, or of at least hsa-miR-320a, or of at least hsa-let-7e, or of at least hsa-let-7f, or of at least hsa-miR-1257, or of at least hs
    Type: Application
    Filed: April 21, 2017
    Publication date: October 31, 2019
    Applicants: Advanced Marker Discovery, S.L., Centro de Investigación Biomédica en Red, Hospital Clinic de Barcelona
    Inventors: Meritxel GIRONELLA COS, Antoni CASTELLS GARANGOU